| |
| Product Information |
Chewable Tablets
Brief Summary: Please consult full package insert for more information.
INDICATIONS: Tri-Heart chewable tablets are indicated for use in prevention of canine heartworm caused by Dirofilaria immitis and for the treatment and control of ascarids (Toxocara canis, Toxascaris leonina) and hookworms (Ancylostoma caninum, Uncinaria stenocephala, Ancylostoma braziliense) in dogs and in puppies six weeks of age.
PRECAUTIONS: All dogs should be tested for existing heartworm infection before starting treatment with Tri-Heart chewable tablets. A mild hypersensitivity-type reaction, presumably due to dead or dying microfilariae and particularly involving a transient diarrhea has been observed in clinical trials with ivermectin alone after treatment of some dogs that have circulating microfilariae.
Keep this and all drugs out of the reach of children. In case of ingestion by humans, clients should be advised to contact a physician immediately. Physicians may contact a Poison Control Center for advice concerning cases of ingestion by humans.
ADVERSE REACTIONS: The following adverse reactions have been reported following the use of ivermectin at the recommended dose: depression/lethargy, vomiting, anorexia, diarrhea, mydriasis, ataxia, staggering, convulsions and hypersalivation.
Caution: Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian.
HOW SUPPLIED: Tri-Heart chewable tablets are available in three dosage strengths for dogs of different weights. Each strength comes in convenient packs of 6 chewable tablets.
Store at controlled room temperature of 59-86° F (15-30° C). Protect product from light.
For technical assistance, call Intervet/Schering-Plough Animal Health 1-800-224-5318.
Manufactured for: Schering-Plough Animal Health Corp., Union NJ 07083
Manufactured by: Heska Corporation, Fort Collins, CO 80525 Made in USA
©2005 Heska Corporation, 27499708, ANADA 200-338, Approved by FDA |
|
|
